Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2014

Significant Accounting Policies [Line Items]

Schedule of ResponseDX Accounts Receivable

ResponseDX^® accounts receivable as of December 31, 2013 and September 30, 2014, consisted of the following:

	December 31,		September 30,
	2013		2014
			(Unaudited)
Net Medicare receivable	$	2,422,611	$	2,377,560
Net Private Payor receivable		4,315,587		5,946,423
		6,738,198		8,323,983
Allowance for doubtful accounts		(2,404,659)		(2,204,177)
Total	$	4,333,539	$	6,119,806

Schedule of Estimated Useful Lives of Property and Equipment

The Company has determined the estimated useful lives of its property and equipment, as follows:

Laboratory equipment	5 to 7 years
Furniture and equipment	3 to 7 years
Leasehold improvements	Shorter of the useful life (5 to 7 years) or the lease term

Schedule of Revenue Sources that Account for Greater than 10 Percent of Total Revenue

Revenue sources that account for greater than 10 percent of total revenue are provided below.

	Three Months Ended September 30,								Nine Months Ended September 30,
	2013				2014				2013				2014
	(Unaudited)								(Unaudited)
			Percent				Percent				Percent				Percent
			of Total				of Total				of Total				of Total
	Revenue		Revenue		Revenue		Revenue		Revenue		Revenue		Revenue		Revenue
GlaxoSmithKline entities:
GlaxoSmithKline, LLC	$	76,792	*	%	$	165,169	*	%	$	579,606	*	%	$	165,169	*	%
GlaxoSmithKline Biologicals S.A.		633,543	16			296,250	*			3,166,288	21			1,017,406	*
Total GlaxoSmithKline entities	$	710,335	17		$	461,419	10		$	3,745,894	25	%	$	1,182,575	*
Medicare, net of contractual allowances	$	956,716	23	%	$	857,786	19	%	$	3,379,405	23	%	$	3,378,203	27	%

* Represents less than 10% of revenue.

Sales Revenue, Net [Member]

Significant Accounting Policies [Line Items]

Schedule of Revenue by Major Customers by Reporting Segments

The following details ResponseDX^® revenue for the periods indicated:

	Three Months				Nine Months
	Ended September 30,				Ended September 30,
	(Unaudited)				(Unaudited)
	2013		2014		2013		2014
Net Medicare revenue	$	956,716	$	857,786	$	3,379,405	$	3,378,203
Net Private Payor revenue		1,584,796		3,059,799		5,450,682		7,538,888
Net ResponseDX® revenue	$	2,541,512	$	3,917,585	$	8,830,087	$	10,917,091

Accounts Receivable [Member]

Significant Accounting Policies [Line Items]

Schedule of Revenue by Major Customers by Reporting Segments

Customers that account for greater than 10 percent of gross accounts receivable are provided below.

	As of December 31, 2013					As of September 30, 2014
						(Unaudited)
			Percent of					Percent of
	Receivable		Total			Receivable		Total
	Balance		Receivables			Balance		Receivables
GlaxoSmithKline entities:
GlaxoSmithKline LLC	$	597,937		*	%	$	145,654		*	%
GlaxoSmithKline Biologicals S.A.	$	544,298		*	%	$	470,957		*	%
Total GlaxoSmithKline entities	$	1,142,235		13	%	$	616,611		*	%
Medicare, net of contractual allowances	$	2,422,611		28	%	$	2,377,560		26	%

* Represents less than 10% of accounts receivable.